OBJECT/V~; To compare the effects of pretreatment with two aspirin regimens and placebo on niacin-induced cutaneous reactions.
I
n patients with established coronary heart disease, beneficial effects of lipid modification with niacin have been demonstrated in various clinical studies. After 15 years of follow up, patients in the Coronary Drug Project had an 11% reduction in total mortality compared with patients who received placebo.1 More recent studies have found that treatment with intensive lipid modifying corn binations of niacin plus bile acid sequestrants resulted in increased rates of plaque regression and stabilization corn pared with less-intensive regimens consisting primarily of dietary modification. ~, 3 Niacin is an effective and inexpensive lipid modifying agent that produces favorable alterations in total cholesterol, low density lipoprotein cholesterol, high density lipo protein cholesterol, and triglycerides. However, bothersome cutmleous reactions, particularly flushing and pruritus. occur with reported incidences ranging from 82% to 100% and often result in niacin discontinuation by patients. 4, 5 Clinicians are reluctmlt to prescribe niacin because of the high rate of noncompliance, despite the favorable effects on lipid profiles. Although the mechanisms producing niacin-induced cutaneous reactions are not completely understood, there is evidence that such reactions are me diated by a transient prostaglandin release. Aspirin and other prostaglandin inhibitors are effective in suppressing these reactions in the majority of patients. r
The dosage of aspirin that most effectively reduces cutmleous reactions to niacin has not been determined precisely. Whelan et al. investigated the effectiveness of placebo and aspirin in doses of 80 rng and 325 rng admin istered 30 minutes prior to a 500-mg dose of niacin/' The 325 mg dose of aspirin was more effective in preventing cutaneous reactions than either 80 rng or placebo, which were not significantly different from each other, Flushing and warmth were reduced by the 325 mg dose, but not itching or tingling. It is possible that higher doses of aspi rin and pretreatment for several days before niacin administration could further reduce cutaneous reactions to niacin, l~' This study evaluated the effects of placebo and ter. None of the subjects had previously taken niacin in doses sufficient to modify plasma lipids, Exclusion criteria included a known hypersensitivity or contraindication to niacin or aspirin: a history of diabetes mellitus, gout, peptic ulcer disease, hepatic dysfunction, renal dysfunction, coagulopathies, or hypotension: and women who were experiencing vasomotor symptoms associated with menopause or who had the potential to become pregnmlt and were not taking adequate birth control. Subjects were not allowed to receive vasoactive drugs or anticoagulants for 1 week before or during the study, They were instructed to refrain from smoking, eating, alcohol, and caffeine containing or hot beverages for at least 2 hours before taking the niacin doses, Subjects received each of the following three regi mens in a randomized crossover fashion: 325 mg of aspirin followed by 500 mg of niacin. 650 mg of aspirin followed by 500 rng of niacin, and placebo followed by 500 mg of niacin. They received either aspirin or placebo for 4 consecutive days and on the fourth day ingested 500 mg of immediate release niacin 30 minutes after taking aspi rin or placebo, The rmldomization procedure was such that subjects had an equal chance of assignment to each of the sLx possible treatment sequences. There was at least a 7-day washout period between each treatment.
Subjects reported the intensity of flushing, pruritus, tingling, warmth, and headache on a 10 cm visual analogue scale, They evaluated these reactions at time 0 (before niacin), and at 15, 30, 60, and 120 minutes following niacin administration.
Comparisons for each reaction were made at each of the four evaluation times (i,e,, 15, 30. 60, and 120 minutes). Two other methods were also used to score the ex tent of the cutaneous reactions, Peak intensity was the highest score recorded at any of the four evaluation times after niacin administration. To quantify a combined mea sure of the intensity and duration of cutaneous reactions.
an intensity-time factor was also calculated by totaling the scores from each of the four evaluation times. Diffe> ences in the extent of the various cutaneous reactions were tested for significance using repeated measures analysis of variance (ANOVA). Post hoc pairwise compari sons with Scheffe's Test were performed in cases in which a significant ANOVA result was obtained. A p value of ,05 or less was considered to be statistically significant for all comparisons.
The proportion of subjects experiencing a reaction of moderate or greater intensity for each of the three regi mens was determined by counting those individuals with at least one score of 6 or higher for any of the five reactions. The X ~ test was used to evaluate differences between the three regimens. The StatMost for Windows (DataMost Corporation. Salt Lake City, Utah) software was used for all statistical analysis.
The study was approved by the Institutional Review Board of the University of Nebraska. Written informed consent was obtained from each subject prior to participation.
RESU LTS
Forty two subjects (22 males and 20 females) were recruited and completed the study, with a mean age of 44.2 years (SD 8.4 years). The subjects were generally in good health. Although 15 subjects reported taking pre scription drugs, few other medical problems were reported by the study participants. Two subjects were re ceiving levothyroxine, while two others were receiving postmenopausal hormone replacement therapy, One subJect was receiving a triphasic oral contraceptive product. Two other subjects had recently converted to purified protein derivative (PPD) positive status and were completing 6 month courses of isoniazid. Two subjects reported well controlled seizure disorders (one treated with phenytoin and the other with phenobarbital). Two other subjects had arthritic disorders: one required both ibuprofen and inject able gold. while the other was treated with ketoprofen. Occasional use of terfenadine for allergies was reported by one subject, while two others were taking antidepressants. One subject used a corticosteroid cream for localized psoriasis, Only 4 (9,5%) of the 42 subjects smoked cigarettes.
The symptom scores for the various cutaneous reac tions are summarized in Table 1 mid graphically displayed in Figures 1-5 , The symptom scores for flushing. itching, tingling, and warmth were all significantly re duced by both aspirin regimens (p < .05 in all cases), al though there were no significmK differences between the 325 rng and 650 rng doses. The results were similar using both the peak intensity and the intensity time factor to measure the extent of the reactions, For each of the four reactions, significant differences in symptom scores were seen between placebo and either of the aspirin regimens at the 30-and 60-minute evaluation times, but not at 15 or 120 minutes. No significant differences were seen at any time between the two aspirin regimens, With regard to headache, the repeated measures ANOVA procedure produced some significant results (p = .050 for peak intensity, p = .039 for intensity time factor, and p .035 at the 30-minute evaluation time), However. pairwise testing with Scheffe's Test did not produce signi5 icant differences between the three regimens. Headache occurred infrequently and was generally of mild intensity. Only 14 (33%) of the 42 subjects reported headache oc curring with any of the three regimens, and only 6 (14%) of the subjects reported any headache intensity of 3 or gre ate r. most commonly used drug and h a s been most extensively studied. We compared placebo with aspirin administered in daily doses of 325 mg mid 650 mg. In an attempt to achieve m a x i m u m prostaglandin inhibition, we adminis tered each of the regimens daily for four doses prior to challenge with a 500-mg dose of immediate-release niacin. We found both aspirin regimens to be significantly better than placebo in reducing symptom scores for flush ing, itching, tingling, mid warmth. However, we did not find the 650 1Ttg dose of aspirin to be any better than 325 rag. This finding was consistent regardless of the method used to compare symptom scores and also when the two regimens were compared on the proportion of subjects ex periencing a reaction of at least moderate severity.
Our findings are similar to those of other investigators and suggest that administering aspirin in doses above 325 rng will provide little additional benefit in re ducing cutaneous reactions due to niacin, Wilkin et al. Compared with placebo, pretreatment with aspirin reduced the intensity of flushing significantly for the two highest niacin doses, b u t even with aspirin pretreatment, the subjects still had substmKial changes in MTCI indicating that flushing still occurred. J a y et al. evaluated aspirin pretreatment in subjects receiving 250 mg of niceritrol, a niacin analogue with a lower potential for c u t a n e o u s reactions compared to niacin, is The 300 1Ttg and 600 1Ttg aspi rin doses both reduced the severity of flushing compared with placebo, b u t there was not a significant difference between the two aspirin regimens.
Our study was not designed to evaluate specifically the effect of aspirin pretreatment for 4 days prior to niacin administration versus the effect of pretreatment with sin gle doses of aspirin. However, when our results are c o m pared with those of Whelan et al., r' it appears that pretreatment beyond a single aspirin dose adds modest benefit at best. The differing methods used in the two studies make direct comparisons problematic, Although Whelan et al. did not report data on the intensity of cutaneous re actions at the 325 mg dose, 72% of the 25 subjects re p o k e d flushing. 72% reported wal~nth, 60o/0 reported itching, and 68% reported tingling. In our study, 17 (41%) of the 42 subjects reported a reaction of moderate or greater T h e b e n e f i c i a l effects of t h e two a s p i r i n r e g i m e n s were s e e n p r i m a r i l y a t t h e 3 0 -m i n u t e a n d 6 0 -m i n u t e e v a l u ation times. E x a m i n a t i o n of F i g u r e s 1 4 reveals t h a t with p l a c e b o a n d b o t h a s p i r i n r e g i m e n s , s u b j e c t s e x p e r i e n c e d a n initial o n s e t of t h e v a r i o u s c u t m l e o u s r e a c t i o n s a t 15 m i n u t e s . T h e r e a c t i o n s c o n t i n u e d to i n c r e a s e w i t h p l m cebo, p e a k i n g a t e i t h e r 3 0 or 6 0 m i n u t e s a f t e r n i a c i n a d m i n i s t r a t i o n . However. a s p i r i n a d m i n i s t r a t i o n b l u n t e d t h e i n t e n s i t y of t h e r e a c t i o n s , so t h a t b y 30 m i n u t e s t h e y were of e q u a l or l e s s e r i n t e n s i t y a s c o m p a r e d w i t h 15 m i n u t e s .
By 120 m i n u t e s , t h e r e a c t i o n s h a d s u b s i d e d to t h e p o i n t w h e r e t h e r e were no s i g n i f i c a n t differences b e t w e e n t h e p l a c e b o a n d two a s p i r i n r e g i m e n s ,
We also e v a l u a t e d the effect of the a s p i r i n r e g i m e n s in p r e v e n t i n g h e a d a c h e . A l t h o u g h a s p i r i n a d m i n i s t r a t i o n h a d no significant effect in p r e v e n t i n g h e a d a c h e , the low incid e n c e a n d i n t e n s i t y of h e a d a c h e i n d i c a t e s t h a t it w a s n o t a p a r t i c u l a r l y i m p o r t m l t r e a c t i o n in m o s t of t h e s u b j e c t s .
A limitation of o u r s t u d y is its lack of p o w e r to d e t e c t small, b u t p o t e n t i a l l y i m p o r t m l t , differences b e t w e e n t h e two a s p i r i n r e g i m e n s . B e c a u s e we h a d no prior k n o w l e d g e of the p o p u l a t i o n s t a n d To h e l p facilitate d e v e l o p m e n t of t o l e r a n c e to n i a c i n reactions, t h e r a p y is u s u a l l y initiated a t d o s a g e s in t h e r a n g e of 100 m g t h r e e tinles daily m i d the d o s a g e is i n c r e a s e d over s e v e r a l weeks, In spite of t h i s strategy, c u t a n e o u s rea c t i o n s to n i a c i n are often u n b e a r a b l e , a n d 3 2 5 m g of aspirin is often given prior to e a c h n i a c i n dose to i m p r o v e its tolerability, P a t i e n t s typically receive final n i a c i n d o s e s r a n g i n g from 1 to 6 g daily on a long t e r m b a s i s . W h e n ni- The Guthors Gcknowledge the Gsdstonce of John P~ GrahGrn, PhGrmD,
